文献速递结核与非结核分枝杆菌艾滋病与性传播感染

利福平或异烟肼在结核感染且合并HIV或其他健康状况者中的安全性和有效性:两项随机试验的事后分析

Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该事后分析纳入两项随机试验中6859例结核感染成人,比较4个月利福平(10 mg/kg/d)与9个月异烟肼(5 mg/kg/d)。在HIV感染者及其他健康状况人群中,利福平完成率不低于或相似于异烟肼,药物相关不良事件在HIV感染者中利福平较异烟肼少(风险差-2.1%,95%CI -5.9至1.6),活动性结核发病率相似。结论认为利福平在包括HIV在内的许多健康状况人群中安全且与异烟肼同样有效。

要点

  • 在HIV感染者中,利福平药物相关不良事件风险较异烟肼低2.1%(95%CI -5.9至1.6)。
  • 利福平与异烟肼在合并其他健康状况人群中活动性结核发病率相似。
  • HIV感染者接受利福平后结核发病率与无健康状况者相当(率差4.1/1000人年,95%CI -6.4至14.7)。

核心结论

  • 利福平在包括HIV感染者在内的许多健康状况人群中安全且与异烟肼同样有效。

研究设计与样本

  • 对两项随机试验进行事后分析,共纳入6859例成人结核感染参与者,按1:1随机接受利福平10 mg/kg/d或异烟肼5 mg/kg/d。

主要发现

  • 总体中270例(3.9%)为HIV感染者(135例接受抗逆转录病毒治疗),2012例(29.3%)有其他健康状况,4577例(66.8%)无健康状况。
  • 在所有人群中,利福平的完成率较异烟肼更高或相似。
  • HIV感染者中利福平的不良事件较异烟肼少(风险差-2.1%,95%CI -5.9至1.6),其他人群一致,但肾衰竭或使用免疫抑制剂者除外(风险差2.1%,95%CI -7.2至11.3)。
  • 接受利福平或异烟肼者结核发病率相似;HIV感染者接受利福平后结核发病率与无健康状况者相当(率差4.1/1000人年,95%CI -6.4至14.7)。

临床怎么用

  • 对于合并HIV或其他健康状况的结核感染人群,可考虑使用4个月利福平方案作为9个月异烟肼方案的替代。

局限性

  • 本研究为事后分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The safety and efficacy of rifampin among people living with human immunodeficiency virus (PLHIV) or other health conditions is uncertain. We assessed completion, safety, and efficacy of 4 months of rifampin vs 9 months of isoniazid among PLHIV or other health conditions. METHODS: We conducted post hoc analysis of 2 randomized trials that included 6859 adult participants with Mycobacterium tuberculosis infection. Participants were randomized 1:1 to 10 mg/kg/d rifampin or 5 mg/kg/d isoniazid. We report completion, drug-related adverse events (AE), and active tuberculosis incidence among people living with HIV; with renal failure or receiving immunosuppressants; using drugs or with hepatitis; with diabetes mellitus; consuming >1 alcoholic drink per week or current/former smokers; and with no health condition. RESULTS: Overall, 270 (3.9%) people were living with HIV (135 receiving antiretroviral therapy), 2012 (29.3%) had another health condition, and 4577 (66.8%) had no condition. Rifampin was more often or similarly completed to isoniazid in all populations. AEs were less common with rifampin than isoniazid among PLHIV (risk difference, -2.1%; 95% confidence interval [CI], -5.9 to 1.6). This was consistent for others except people with renal failure or on immunosuppressants (2.1%; 95% CI, -7.2 to 11.3). Tuberculosis incidence was similar among people receiving rifampin or isoniazid. Among participants receiving rifampin living with HIV, incidence was comparable to those with no health condition (rate difference, 4.1 per 1000 person-years; 95% CI, -6.4 to 14.7). CONCLUSIONS: Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV. CLINICAL TRIALS REGISTRATION: NCT00170209; NCT00931736.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Campbell JR, Al-Jahdali H, Bah B, et al. Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clin Infect Dis. 2021. PMID: 32785709. doi:10.1093/cid/ciaa1169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。